Can Cepheid Power Past $25?

 |  About: CEPHEID (CPHD)
by: Marlowe Cassetti

Each day I perform an analysis on all the members of the US stock market traded issues plus Exchange Traded Funds/Closed End Funds [ETF/CEF]. I use a Rocket Science Investing [RSI] methodology which incorporates Hurst Channel analysis, money flow, six-month price potential, and a confirming price breakout. For stocks, RSI adds fundamental metrics to the algorithm.

Yesterday, the ETF analysis came up with three energy ETFs and the stock scan came up with four stocks that look to me to be in industries I would characterize as recession proof. One stock, Cepheid Inc (CPDH), interests me.

Cepheid is a molecular diagnostics company that develops, manufactures and markets integrated systems for testing in the clinical molecular diagnostics, industrial and biothreat markets. The Company's systems enable genetic testing of organisms by automating otherwise complex manual laboratory procedures. This sounds exciting to me, automating the DNA testing process has to be a killer application.

Let's take a look at a chart of CPHD: Cepheid has been a steller performer - up almost 175% over the past 12 months. I am impressed at its red hot climb this year. It has had a problem punching through, and staying above, the $25 level. In technician's parlance this is resistance. If you are interested in Cepheid Inc, you may wish to monitor its progress in challenging the $25 mark and jumping on it if and when CPHD wins the contest.

Disclosure: none